US 11,654,217 B2
Antimicrobial compositions comprising minocycline and oxidized cellulose
Eve Montia, Rehovot (IL); Dwayne Looney, Flemington, NJ (US); Theresa Scheuble, Rockaway, NJ (US); Ronen Eavri, Binyamina (IL); and Roi Mashiach, Rehovot (IL)
Assigned to OMRIX BIOPHARMACEUTICALS LTD., Rehovot (IL); and ETHICON, INC., Somerville, NJ (US)
Filed by Omrix Biopharmaceuticals Ltd., Rehovot (IL); and Ethicon, Inc., Somerville, NJ (US)
Filed on Apr. 12, 2021, as Appl. No. 17/228,432.
Application 17/228,432 is a division of application No. 16/195,895, filed on Nov. 20, 2018, granted, now 11,000,635.
Claims priority of provisional application 62/598,662, filed on Dec. 14, 2017.
Claims priority of application No. 256312 (IL), filed on Dec. 14, 2017.
Prior Publication US 2021/0228783 A1, Jul. 29, 2021
Int. Cl. A61L 31/16 (2006.01); A61K 31/717 (2006.01); A61P 31/04 (2006.01); A61K 31/65 (2006.01); A61L 15/28 (2006.01); A61L 15/44 (2006.01); A61L 26/00 (2006.01)
CPC A61L 31/16 (2013.01) [A61K 31/65 (2013.01); A61K 31/717 (2013.01); A61L 15/28 (2013.01); A61L 15/44 (2013.01); A61L 26/0023 (2013.01); A61P 31/04 (2018.01); A61L 26/0066 (2013.01); A61L 2300/404 (2013.01)] 8 Claims
 
1. A method for the treatment of an infection in a subject in need thereof, the method comprising administering to the subject an antimicrobial composition comprising an oxidized regenerated cellulose (ORC) in a solid form and an antibiotic being minocycline, wherein the minocycline is dispersed or impregnated on and/or within the ORC solid and is present at an effective concentration of from about 0.013 to about 0.105 μg per cm2 of ORC.